Positive inotropic and lusitropic effects of intravenous flosequinan in patients with heart failure
Authors:
- Marc J. SemigranMSMarc J. Semigran
- G.WIlliam DecGDG.WIlliam Dec
- Charles A. BoucherCBCharles A. Boucher
- Michael A. FiferMFMichael A. Fifer
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Clinical efficacy of flosequinan in heart failureAmerican Heart Journal, 1991
- Flosequinan: A vasodilator with positive inotropic activityAmerican Heart Journal, 1991
- Exercise capacity, hemodynamic, and neurohumoral changes following acute and chronic administration of flosequinan in chronic congestive heart failureCardiovascular Drugs and Therapy, 1990
- Chronic vasodilator therapy with flosequinan in congestive heart failureClinical Cardiology, 1990
- Positive Inotropy Contributes to the Hemodynamic Mechanism of Action of Flosequinan (BTS 49465) in the Intact DogJournal of Cardiovascular Pharmacology, 1990
- Positive Inotropic and Hemodynamic Properties of Flosequinan, a New Vasodilator, and a Sulfone MetaboliteJournal of Cardiovascular Pharmacology, 1989
- Central and regional hemodynamic effects of flosequinan for congestive heart failureThe American Journal of Cardiology, 1989
- Effect of flosequinan on exercise capacity and symptoms in severe heart failure.Heart, 1989
- Cardiovascular effects of the novel arteriovenous dilator agent, flosequinan in conscious dogs and catsBritish Journal of Pharmacology, 1988
- Hemodynamic effects of BTS 49465, a new long-acting systemic vasodilator drug, in patients with severe congestive heart failureAmerican Heart Journal, 1987